Чланци са овлашћеним јавним приступом - Gerburg WulfСазнајте више
Доступно негде: 60
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
WJ Israelsen, TL Dayton, SM Davidson, BP Fiske, AM Hosios, G Bellinger, ...
Cell 155 (2), 397-409, 2013
Овлашћења: US National Institutes of Health
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
C Pantelidou, O Sonzogni, M De Oliveria Taveira, AK Mehta, A Kothari, ...
Cancer discovery 9 (6), 722-737, 2019
Овлашћења: US National Institutes of Health, Susan G. Komen
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ...
Cancer discovery 2 (11), 1048-1063, 2012
Овлашћења: US National Institutes of Health
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ...
Journal of Clinical Oncology 38 (36), 4274-4282, 2020
Овлашћења: Susan G. Komen
Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton
H Hu, A Juvekar, CA Lyssiotis, EC Lien, JG Albeck, D Oh, G Varma, ...
Cell 164 (3), 433-446, 2016
Овлашћења: US National Science Foundation, US National Institutes of Health, Damon …
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ...
JAMA oncology 5 (8), 1132-1140, 2019
Овлашћења: US National Institutes of Health
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
PK Morrow, GM Wulf, J Ensor, DJ Booser, JA Moore, PR Flores, Y Xiong, ...
Journal of Clinical Oncology 29 (23), 3126-3132, 2011
Овлашћења: US National Institutes of Health
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
Овлашћења: US National Institutes of Health
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Y Xing, NU Lin, MA Maurer, H Chen, A Mahvash, A Sahin, A Akcakanat, ...
Breast Cancer Research 21, 1-12, 2019
Овлашћења: US National Institutes of Health, Cancer Prevention Research Institute of …
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors
BM Emerling, JB Hurov, G Poulogiannis, KS Tsukazawa, R Choo-Wing, ...
Cell 155 (4), 844-857, 2013
Овлашћења: US National Institutes of Health
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
Овлашћења: US National Institutes of Health
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
K Koikawa, S Kibe, F Suizu, N Sekino, N Kim, TD Manz, BJ Pinch, ...
Cell 184 (18), 4753-4771. e27, 2021
Овлашћења: US National Institutes of Health
Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer
Q Li, T Qin, Z Bi, H Hong, L Ding, J Chen, W Wu, X Lin, W Fu, F Zheng, ...
Nature communications 11 (1), 1456, 2020
Овлашћења: National Natural Science Foundation of China
Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics
JF Liu, S Palakurthi, Q Zeng, S Zhou, E Ivanova, W Huang, ...
Clinical Cancer Research 23 (5), 1263-1273, 2017
Овлашћења: US National Institutes of Health
Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance
TH Lee, A Tun-Kyi, R Shi, J Lim, C Soohoo, G Finn, M Balastik, ...
Nature cell biology 11 (1), 97-105, 2009
Овлашћења: US National Institutes of Health
Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations
TL Yuan, G Wulf, L Burga, LC Cantley
Current biology 21 (3), 173-183, 2011
Овлашћења: US National Institutes of Health
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
A Juvekar, H Hu, S Yadegarynia, CA Lyssiotis, S Ullas, EC Lien, ...
Proceedings of the National Academy of Sciences 113 (30), E4338-E4347, 2016
Овлашћења: US National Institutes of Health
Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem–like cell traits in breast cancer
ML Luo, C Gong, CH Chen, DY Lee, H Hu, P Huang, Y Yao, W Guo, ...
Cancer research 74 (13), 3603-3616, 2014
Овлашћења: US National Institutes of Health, National Natural Science Foundation of …
The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation
ML Luo, C Gong, CH Chen, H Hu, P Huang, M Zheng, Y Yao, S Wei, ...
Cell reports 11 (1), 111-124, 2015
Овлашћења: US National Institutes of Health, National Natural Science Foundation of …
Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability
PB Lam, LN Burga, BP Wu, EW Hofstatter, KP Lu, GM Wulf
Molecular cancer 7, 1-12, 2008
Овлашћења: US National Institutes of Health
Публикације и информације о финансирању аутоматски одређује рачунарски програм